Keith J. Kendall, CEO and President at Aquestive Therapeutics, Inc. (AQST), bought 8,000 shares at $3.93 ($31K) on 2019-08-09, disclosed to the SEC on 2019-08-20.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.84 | 2,000 | $8K | 24.8% |
| 2 | $3.93 | 1,000 | $4K | 12.7% |
| 3 | $4.00 | 2,000 | $8K | 25.8% |
| 4 | $4.05 | 1,000 | $4K | 13.1% |
| 5 | $3.65 | 1,000 | $4K | 11.8% |
| 6 | $3.70 | 1,000 |
| $4K |
| 11.9% |
| Total | $3.88 avg | 8,000 | $31K | 100% |
| Filing → |
| AQST | BUY | 2018-11-26 | $80K | — | Filing → |